Acadia Healthcare Company, Inc. Q2 2025 results
Snapshot
Acadia Healthcare Company, Inc. reported $869M of revenue in Q2 2025, up 9.2% year over year, with diluted EPS of $0.33 and an operating margin of 8.8%.
- Revenue
- $869M
- YoY growth
- +9.2%
- Diluted EPS
- $0.33
- Operating margin
- 8.8%
What management said
- •We're pleased with our progress to date in 2025 as we continue to execute our strategy in line with our growth objectives.
- •For the full year 2025, we expect gross revenue of approximately $230 million from existing state Medicaid supplemental programs.
- •More than half of this revenue comes from states that may begin reducing these payments starting in fiscal 2028 if proposed changes to the programs are implemented.
- •If these changes occur, we also anticipate that a portion of the revenue loss would be offset by a reduction in the provider taxes we pay in those states.
- •We saw strong performance in our specialty and CTC lines of business, with same facility growth in the mid single digits for each, consistent with our expectations.
- •More broadly, volumes in our acute care business came in slightly below expectations, while demand across the majority of our business remains robust.
- •Over the last two years, Heather has been instrumental in strengthening our financial foundation and advancing our growth strategy.
- •We reported $869.2 million in revenue for the quarter, representing a 9.2% increase over the second quarter of last year.
- •Adjusted EBITDA for the second quarter of 2025 was $201.8 million, reflecting an Adjusted EBITDA margin of 23.2%.
- •Same facility revenue grew 9.5% year-over-year, including a 7.5% increase in revenue per patient day and 1.8% growth in patient days.
- •On a same facility basis, Adjusted EBITDA was $256 million and Adjusted EBITDA margin was 30.1% in the second quarter of this year.
- •Looking at the balance sheet, maintaining a strong financial position remains a top priority while providing us with sufficient capital to make strategic investments in our business.
What went well
- •Second quarter 2025 revenue of $869.2 million grew 9.2% over the prior-year quarter, and Adjusted EBITDA of $201.8 million increased 7.5% with a 23.2% Adjusted EBITDA margin.
- •Same-facility revenue grew 9.5% year-over-year, including a 7.5% increase in revenue per patient day and 1.8% growth in patient days.
- •The State of Tennessee approved a new directed payment program, producing a $51.8 million favorable pre-tax benefit in the quarter and an expected $40-$45 million recurring annual run-rate benefit.
- •Specialty and CTC lines of business each delivered mid-single-digit same-facility growth, consistent with expectations, and commercial and Medicare acute volumes rose 9% and 8% respectively.
- •The company added 479 beds year-to-date in 2025, completed construction of three new joint venture facilities, and expanded to 174 CTCs across 33 states.
- •Labor trends improved, with wage growth coming down to roughly 3.5% in Q2 and reduced premium costs, supported by centralized recruitment and retention initiatives.
What went wrong
- •Same-facility patient days increased only 1.8%, slightly below expectations, driven by weaker Medicaid volumes in the acute care business that came in below plan.
- •Medicaid volumes at acute hospitals were down slightly year-over-year, and performance deteriorated at one facility facing strong local market and media pressures.
- •Startup losses rose to $14.2 million from $4.6 million in Q2 2024 due to an accelerated facility opening pace.
- •The company spent roughly $54 million during the quarter on government investigations, and the underperforming-facility EBITDA drag is running about $3 million worse than the originally anticipated $20 million for the year.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Full-year Adjusted EBITDA | FY2025 | prior range (implied higher) | $675M-$700M | updated |
| Full-year same-facility volume growth | FY2025 | low to mid single digits | 2%-3% | lowered |
| Full-year startup losses | FY2025 | approx $50M (implied) | $60M-$65M | raised ~$10M |
| Full-year total beds added | FY2025 | 800-1,000 | 950-1,000 | raised at midpoint |
| Full-year net Medicaid supplementals | FY2025 | flat to up $15M | +$30M-$40M | raised |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Total revenue | +9.2% to $869.2M | solid top-line growth in line with growth objectives |
| Adjusted EBITDA | +7.5% to $201.8M | revenue growth, including Tennessee supplemental benefit, partly offset by higher startup losses and softer Medicaid volumes |
| Same-facility revenue | +9.5% | 7.5% increase in revenue per patient day and 1.8% growth in patient days |
| Same-facility patient days | +1.8% | weaker Medicaid acute volumes, slightly below expectations |
| Acute commercial and Medicare volumes | +9% and +8% | managed care team securing commercial and Medicare contracts to diversify payer mix |
| Startup losses | $14.2M vs $4.6M prior year | accelerated facility opening pace |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Medicaid acute volumes | robust demand assumed | weaker Medicaid acute volumes from evolving managed Medicaid utilization patterns and elevated cost pressures | softening |
| Supplemental payments | flat to up $15M expected | Tennessee program approved; net supplementals now +$30M-$40M with $40-$45M recurring run-rate | improving |
| Capital allocation | build up to 1,000 beds in 2025 | taking a harder look at the pipeline; two facilities paused saving over $100M in CapEx, potentially accelerating free cash flow positive ahead of end-2026 | tightening |
| Labor | high watermarks a few years back | wage growth down to ~3.5%, reduced premium costs and stability | improving |
| Government investigations | ongoing DOJ and SEC cooperation | ~$54M spent in Q2, much of the independent review done in first half, reduction expected in second half | expected to moderate |
| Underperforming facilities | ~$20M full-year EBITDA headwind assumed | running ~$3M worse, driven by one facility with local media pressure | slightly worse |
Q&A summary
What exactly are you seeing in Medicaid, is it length-of-stay approvals or fewer referrals, and is it specific to Acadia?
The primary driver was weaker Medicaid volumes in acute care, reflecting evolving utilization patterns among managed Medicaid plans navigating elevated cost pressures; there is natural provider-payer tension and the company continues engaging constructively on access and outcomes.
Is the $10 million increase in startup costs from accelerating programs or slower ramps?
It is an accelerated opening pace allowing beds to open more quickly than anticipated, pulling startup costs forward into 2025, which means 2026 startup losses should decline even more than originally expected.
Is there an opportunity to pull forward the free cash flow positive outlook in 2026?
Yes; given policy uncertainty from the reconciliation bill, the company is taking a harder look at capital spending and has paused two pipeline facilities saving over $100 million in CapEx, which can accelerate the path to free cash flow positive and unlock near-term EBITDA.
How much did underperforming facilities drag same-store patient days and has the $20 million loss estimate changed?
They reduced same-facility patient volume growth by about 80 basis points in Q2; the full-year drag is now about $3 million worse than the originally anticipated $20 million, attributable to the one closely watched facility.
What are you seeing on wages and labor expense?
Good improvement and consistency, with reduced premium costs; wage growth has come down to roughly the 3.5% range in Q2 with stability, well below earlier high watermarks.
Of the $230 million in Medicaid supplemental revenue, why does more than half come from states that may reduce payments in fiscal 2028?
Confirmed correct: more than half comes from states where the program rates are above Medicare and thus may be reduced starting fiscal 2028 if proposed changes are implemented, with a portion of any revenue loss offset by reduced provider taxes.